Broad Patent Claims Come Before the Supreme Court in Amgen v Sanofi

S Sean Tu; Sarosh Nagar; Victor L Van de Wiele

doi:10.1001/jama.2023.5638

Broad Patent Claims Come Before the Supreme Court in Amgen v Sanofi

JAMA. 2023 May 16;329(19):1641-1642. doi: 10.1001/jama.2023.5638.

Authors

S Sean Tu^{1

2}, Sarosh Nagar^{1

3}, Victor L Van de Wiele¹

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² West Virginia University College of Law, Morgantown.
³ Harvard University, Cambridge, Massachusetts.

PMID: 36972066
DOI: 10.1001/jama.2023.5638

No abstract available

Plain language summary

This Viewpoint discusses a current Supreme Court lawsuit, Amgen v Sanofi, involving Amgen’s broad patents on PCSK9 that could effectively prevent other manufacturers from producing similar or even clinically superior antibodies, with important negative consequences for patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Patents as Topic* / legislation & jurisprudence
Supreme Court Decisions*
United States